Study S000122

A Multicenter, Randomized, Open-Label, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide(Wegovy®) in Adult Obese or Overweight Subjects

ClinicalTrials.gov record

Registration

Registration: NCT07150975
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 420
Start: 2025-09-23
Primary completion: 2027-06-30
Lead sponsor: Gan & Lee Pharmaceuticals.
Conditions: Obesity/Overweight in Adult
Interventions: DRUG:GZR18; DRUG:Semaglutide(Wegovy® )
Results posted: FALSE

Registered primary outcomes

Percentage change in body weight from baseline after 52 weeks (W) of treatment. [From Week 0 to Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.